Sonnet BioTherapeutics Gives Fiscal 12 months 2022 Second Quarter Enterprise and Earnings Replace

  • IND for SON-1010 cleared by FDA with first affected person dosed in trial for superior stable tumors
  • SON-080 on monitor to start scientific research by mid-2022
  • Preclinical information for SON-1010, SON-1210, and SON-1410 offered on the 2022 AACR Annual Assembly
  • Preclinical improvement of further FHAB pipeline belongings progressing ahead

PRINCETON, NJ / ACCESSWIRE / Could 10, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Firm”), a biopharmaceutical firm growing modern focused biologic medication, introduced as we speak its monetary outcomes for the three and 6 months ended March 31, 2022 and offered a enterprise replace.

“We’re excited to have initiated the primary scientific trial with our lead Totally Human Albumin Binding pipeline asset, SON-1010,” stated Pankaj Mohan, Ph.D., Founder and CEO. “This represents an ideal accomplishment for our analysis staff, and we sit up for persevering with the progress by additionally advancing SON-080 into the clinic by mid-year. Moreover, we plan to provoke a non-human primate non-GLP toxicology examine for SON-1210 later this quarter.”

“We proceed to give attention to our financing technique and are on monitor with our R&D actions in 2022. We consider there’s vital worth in our pipeline that’s not mirrored in our present valuation that we are going to search to unlock throughout this pivotal 12 months for Sonnet,” commented Jay Cross, CFO.

FY 2022 Second Quarter and Current Company Updates

Sonnet offered the next company updates for the 2022 calendar 12 months:

  • IND cleared for SON-1010 and scientific trial initiated; preliminary security information for this examine are anticipated within the second half of 2022.
  • Continued cGMP manufacturing of SON-080, with scientific examine initiation deliberate for the primary half of 2022 in sufferers with Chemotherapy Induced Peripheral Neuropathy (CIPN).
  • Getting ready initiation of a non-GLP pre-clinical toxicity examine of SON-1210 in non-human primatesin the second quarter of 2022.
  • Accomplished sequence affirmation for SON-3015 and getting ready for preliminary in vivo mice research within the second half of 2022.
  • Lead optimization is underway to provoke chemistry, manufacturing and controls (CMC) with cell line improvement for SON-1410 within the second quarter of 2022.

FY 2022 Second Quarter Ended March 31, 2022 Monetary Outcomes

  • As of March 31, 2022, Sonnet had $13.6 million money readily available.
  • Analysis and improvement bills had been $6.4 million for the three months ended March 31, 2022, in comparison with $3.8 million for the three months ended March 31, 2021. The rise of $2.6 million was primarily because of the improvement of the cell traces for SON-1010, SON-1210 and SON-080, and a rise in payroll and share-based compensation expense as we proceed to develop our operations.
  • Common and administrative bills had been $1.9 million for the three months ended March 31, 2022, in comparison with $2.2 million for the three months ended March 31, 2021. The lower of $0.3 million was primarily as a result of a lower in payroll expense.

About Sonnet BioTherapeutics Holdings, Inc.

Based in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology firm with a proprietary platform for innovating biologic medication of single or bispecific motion. Often known as FHAB (Totally Human Albumin Binding), the know-how makes use of a totally human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to focus on tissues. FHAB is the muse of a modular, plug-and-play assemble for potentiating a spread of huge molecule therapeutic lessons, together with cytokines, peptides, antibodies and vaccines.

Ahead-Trying Statements

This press launch incorporates sure forward-looking statements throughout the that means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934 and Personal Securities Litigation Reform Act, as amended, together with these regarding the Firm’s product improvement, scientific and regulatory timelines, market alternative, aggressive place, potential or assumed future outcomes of operations, enterprise methods, potential development alternatives and different statements which might be predictive in nature. These forward-looking statements are primarily based on present expectations, estimates, forecasts and projections concerning the business and markets during which we function and administration’s present beliefs and assumptions.

These statements could also be recognized by way of forward-looking expressions, together with, however not restricted to, “anticipate,” “anticipate,” “intend,” “plan,” “consider,” “estimate,” “potential, “predict,” “venture,” “ought to,” “would” and related expressions and the negatives of these phrases. These statements relate to future occasions or our monetary efficiency and contain identified and unknown dangers, uncertainties, and different components which can trigger precise outcomes, efficiency or achievements to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking statements. Such components embody these set forth within the Firm’s filings with the Securities and Change Fee. Potential traders are cautioned to not place undue reliance on such forward-looking statements, which communicate solely as of the date of this press launch. The Firm undertakes no obligation to publicly replace any forward-looking assertion, whether or not because of new info, future occasions or in any other case.

Sonnet BioTherapeutics Investor Contact

Michael V. Morabito, Ph.D.

Solebury Trout


[email protected]

Sonnet BioTherapeutics Holdings, Inc.

Consolidated Stability Sheets


    March 31,     September 30,  
    2022     2021  



Present belongings:



  $ 13,635,528     $ 27,622,067  

Pay as you go bills and different present belongings

    1,280,133       1,189,474  

Complete present belongings

    14,915,661       28,811,541  

Property and gear, internet

    52,634       59,056  

Working lease right-of-use asset

    78,000       123,213  

Complete belongings

  $ 15,046,295     $ 28,993,810  

Liabilities and stockholders’ fairness


Present liabilities:


Associated-party notes

  $ 748     $ 748  

Accounts payable

    4,036,420       3,781,299  

Accrued bills

    2,104,936       2,310,410  

Working lease legal responsibility

    79,603       94,520  

Deferred revenue

    291,255       516,374  

Complete present liabilities

    6,512,962       6,703,351  

Working lease legal responsibility


Complete liabilities

    6,512,962       6,733,963  

Stockholders’ fairness:


Most well-liked inventory; $0.0001 par worth: 5,000,000 shares licensed. No shares issued or excellent


Frequent inventory; $0.0001 par worth: 125,000,000 shares licensed; 60,263,137 and 60,250,637 issued and excellent at March 31, 2022 and September 30, 2021, respectively

    6,026       6,025  

Further paid-in capital

    84,626,005       83,943,040  

Gathered deficit

    (76,098,698 )     (61,689,218 )

Complete stockholders’ fairness

    8,533,333       22,259,847  

Complete liabilities and stockholders’ fairness

  $ 15,046,295     $ 28,993,810  

See 10-Q filed as we speak for notes to consolidated monetary statements

Sonnet BioTherapeutics Holdings, Inc.

Consolidated Statements of Operations




Three Months Ended

March 31,


Six Months Ended

March 31,

    2022     2021     2022     2021  

Collaboration income

  $ 95,320     $     $ 225,119     $  

Working bills:


Analysis and improvement

    6,405,273       3,840,399       10,671,138       7,706,407  

Common and administrative

    1,900,263       2,196,632       3,979,149       4,194,617  

Complete working bills

    8,305,536       6,037,031       14,650,287       11,901,024  

Loss from operations

    (8,210,216 )     (6,037,031 )     (14,425,168 )     (11,901,024 )

Overseas trade achieve (loss)

    1,717       (2,076 )     15,688       (15,323 )

Internet loss

  $ (8,208,499 )   $ (6,039,107 )   $ (14,409,480 )   $ (11,916,347 )

Per share info:


Internet loss per share, primary and diluted

  $ (0.14 )   $ (0.32 )   $ (0.24 )   $ (0.66 )

Weighted common shares excellent, primary and diluted

    60,294,838       18,742,926       60,293,914       17,972,329  

See 10-Q filed as we speak for notes to consolidated monetary statements

SOURCE: Sonnet BioTherapeutics, Inc.


View supply model on